2010
DOI: 10.1111/j.1423-0410.2010.01415.x
|View full text |Cite
|
Sign up to set email alerts
|

Biochemical, molecular and preclinical characterization of a double‐virus‐reduced human butyrylcholinesterase preparation designed for clinical use

Abstract: Extensive preclinical safety and pharmacokinetic testing confirmed that this hBChE preparation can be used for further efficacy testing as a bioscavenger for toxic organophosphate compounds in appropriate animal models and ultimately in humans.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
31
0

Year Published

2011
2011
2022
2022

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 31 publications
(34 citation statements)
references
References 37 publications
3
31
0
Order By: Relevance
“…And it identified no deficits in motor performance, no sign of tissue damage in liver, muscle, or heart, and no effect on maze memory and learning, either with hdAD or AAV. It is not likely that human recipients could tolerate equivalent doses of viral vector, but a large body of evidence supports the idea that BChE in native and mutant forms is itself benign even at very high levels (Weber et al, 2011).…”
mentioning
confidence: 97%
“…And it identified no deficits in motor performance, no sign of tissue damage in liver, muscle, or heart, and no effect on maze memory and learning, either with hdAD or AAV. It is not likely that human recipients could tolerate equivalent doses of viral vector, but a large body of evidence supports the idea that BChE in native and mutant forms is itself benign even at very high levels (Weber et al, 2011).…”
mentioning
confidence: 97%
“…Multiple studies have shown negligible physiologic, biochemical, neurobehavioral, and neuromuscular toxicity from BChE injections and gene transfer (Saxena et al, 2005(Saxena et al, , 2011Brimijoin et al, 2008;Weber et al, 2011;Murthy et al, 2014aMurthy et al, ,b, 2015. Nonetheless, the issue of cardiovascular safety needs closer attention.…”
Section: Introductionmentioning
confidence: 99%
“…Heavy chain H4 of this protein has potential diagnostic value, and it has also been topic of proteomic and glycomic analysis [154]. Weber et al [155] recently described an industrial scale process for production of butyrylcholinesterase. This plasma protein is a candidate for the treatment of poisoning caused by organophosphorous nerve agents.…”
Section: Further Plasma Proteins Considered For Therapeutic Usementioning
confidence: 99%